Lori Freedman Buys 9,022 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) insider Lori Freedman acquired 9,022 shares of the stock in a transaction dated Friday, June 6th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $26,975.78. Following the completion of the transaction, the insider now owns 846,459 shares of the company’s stock, valued at $2,530,912.41. This trade represents a 1.08% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Lori Freedman also recently made the following trade(s):

• On Thursday, June 5th, Lori Freedman acquired 142,379 shares of Organogenesis stock. The shares were purchased at an average cost of $2.91 per share, with a total value of $414,322.89.
• On Wednesday, June 4th, Lori Freedman acquired 100,863 shares of Organogenesis stock. The stock was acquired at an average price of $2.82 per share, with a total value of $284,433.66.

Organogenesis Price Performance

Organogenesis stock opened at $3.03 on Friday. Organogenesis Holdings Inc. has a 12 month low of $2.28 and a 12 month high of $6.71. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The business’s 50 day simple moving average is $3.82 and its 200 day simple moving average is $3.85. The company has a market cap of $384.37 million, a price-to-earnings ratio of -50.50 and a beta of 1.63.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). The firm had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. Sell-side analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley increased their price objective on Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th.

Hedge Funds Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its stake in shares of Organogenesis by 10.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company’s stock worth $187,000 after purchasing an additional 4,239 shares in the last quarter. CWM LLC lifted its holdings in shares of Organogenesis by 8.9% in the 1st quarter. CWM LLC now owns 63,894 shares of the company’s stock valued at $276,000 after acquiring an additional 5,239 shares during the last quarter. Millennium Management LLC raised its position in Organogenesis by 2.8% in the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company’s stock worth $667,000 after purchasing an additional 5,765 shares during the period. ProShare Advisors LLC raised its position in Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after purchasing an additional 6,689 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Organogenesis by 7.1% during the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company’s stock worth $369,000 after acquiring an additional 7,621 shares during the period. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.